Drug
Las41003
Las41003: highest development phase Phase 2, developed by Almirall. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Almirall
Trials
| Drug | Phase | Indication |
|---|---|---|
| LAS41003 NCT01102387 | Phase 2 | Candidiasis |
| LAS41003 NCT01096472 | Phase 2 | Tinea Pedis |
Latest
No recent events.
Follow Las41003 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.